170 related articles for article (PubMed ID: 20950840)
21. Different sensitivities of various thromboplastins to two blood collection systems for monitoring oral anticoagulant therapy.
van den Besselaar AM; Bertina RM; van der Meer FJ; den Hartigh J
Thromb Haemost; 1999 Jul; 82(1):153-4. PubMed ID: 10456474
[No Abstract] [Full Text] [Related]
22. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy.
Fairweather RB; Ansell J; van den Besselaar AM; Brandt JT; Bussey HI; Poller L; Triplett DA; White RH
Arch Pathol Lab Med; 1998 Sep; 122(9):768-81. PubMed ID: 9740135
[TBL] [Abstract][Full Text] [Related]
23. [Heparin and monitoring of peroral anticoagulant therapy].
Bremmelgaard A
Ugeskr Laeger; 1986 May; 148(21):1275-6. PubMed ID: 3727111
[No Abstract] [Full Text] [Related]
24. Reliability of an intravenous intermittent access port (saline lock) for obtaining blood samples for coagulation studies.
Arrants J; Willis ME; Stevens B; Gripkey L; Herman JA; Hernandez-Brooks L; Eaker JE
Am J Crit Care; 1999 Sep; 8(5):344-8. PubMed ID: 10467472
[TBL] [Abstract][Full Text] [Related]
25. Effects of standard unfractionated and low-molecular-weight heparins on platelets of patients undergoing total hip replacement surgery.
Aulmann M; Kwasniki S; Böttiger BW; Meeder PJ
Beitr Infusionsther Transfusionsmed; 1997; 34():242-7. PubMed ID: 9356680
[TBL] [Abstract][Full Text] [Related]
26. Ximelagatran, a new oral anticoagulant--how will it affect laboratory practice? A clinical perspective.
Machin SJ
Lab Hematol; 2004; 10(3):172-3. PubMed ID: 15529439
[No Abstract] [Full Text] [Related]
27. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy.
Olson JD; Arkin CF; Brandt JT; Cunningham MT; Giles A; Koepke JA; Witte DL
Arch Pathol Lab Med; 1998 Sep; 122(9):782-98. PubMed ID: 9740136
[TBL] [Abstract][Full Text] [Related]
28. Discard volumes necessary for clinically useful coagulation studies from heparinized Hickman catheters.
Mayo DJ; Dimond EP; Kramer W; Horne MK
Oncol Nurs Forum; 1996 May; 23(4):671-5. PubMed ID: 8735325
[TBL] [Abstract][Full Text] [Related]
29. The Impact of the Anticoagulant Type in Blood Collection Tubes on Circulating Extracellular Plasma MicroRNA Profiles Revealed by Small RNA Sequencing.
Zhelankin AV; Iulmetova LN; Sharova EI
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142259
[TBL] [Abstract][Full Text] [Related]
30. Trisodium citrate: an alternative to unfractionated heparin for hemodialysis catheter dwells.
Pierce DA; Rocco MV
Pharmacotherapy; 2010 Nov; 30(11):1150-8. PubMed ID: 20973688
[TBL] [Abstract][Full Text] [Related]
31. Heparin therapy and monitoring: a role for the chromogenic antifactor Xa assay.
Rosén S; Casoni MC
Am Clin Lab; 2001 Aug; 20(7):35-8. PubMed ID: 11570272
[No Abstract] [Full Text] [Related]
32. Use of peripheral venous access devices for obtaining blood samples for measurement of activated partial thromboplastin times.
Prue-Owens KK
Crit Care Nurse; 2006 Feb; 26(1):30-2, 34-8. PubMed ID: 16443808
[No Abstract] [Full Text] [Related]
33. Utilising a hybrid anti-Xa calibration assay in unfractionated heparin (UFH) monitoring: validation of assay and its correlation with activated partial thromboplastin time (aPTT).
Lukito P; Collecutt M; Dauer R; Morgan S; Tran H
Pathology; 2016 Aug; 48(5):501-3. PubMed ID: 27306575
[No Abstract] [Full Text] [Related]
34. Nomograms for the administration of unfractionated heparin.
Grubb H; Lovett J; Kingman HM; Copplestone JA; Prentice AG
Thromb Haemost; 2001 Mar; 85(3):565. PubMed ID: 11307835
[No Abstract] [Full Text] [Related]
35. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
Hull RD; Pineo GF; Stein P
Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
[TBL] [Abstract][Full Text] [Related]
36. Monitoring unfractionated heparin with the aPTT: time for a fresh look.
Eikelboom JW; Hirsh J
Thromb Haemost; 2006 Nov; 96(5):547-52. PubMed ID: 17080209
[TBL] [Abstract][Full Text] [Related]
37. Contamination of coagulation tests with heparin from blood gas samples.
Brown JM; Dimeski G
Br J Anaesth; 2001 Oct; 87(4):628-9. PubMed ID: 11878734
[TBL] [Abstract][Full Text] [Related]
38. Lost in (Clinical) Translation: Recent Advances in Heparin Neutralization and Monitoring.
Ourri B; Vial L
ACS Chem Biol; 2019 Dec; 14(12):2512-2526. PubMed ID: 31682398
[TBL] [Abstract][Full Text] [Related]
39. Monitoring heparin therapy by the activated partial thromboplastin time--the effect of pre-analytical conditions.
van den Besselaar AM; Meeuwisse-Braun J; Jansen-Grüter R; Bertina RM
Thromb Haemost; 1987 Apr; 57(2):226-31. PubMed ID: 3603414
[TBL] [Abstract][Full Text] [Related]
40. Interpreting coagulation assays.
Green D
Blood Coagul Fibrinolysis; 2010 Sep; 21 Suppl 1():S3-6. PubMed ID: 20855988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
